ubiquitously expressed prefoldin like chaperoneGenealiases: ART-27 · SKP2 · STAP1
Q-omics provides the consensus-scored UXT profile across patient tissues and cancer cell-line models. UXT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, UXT is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, UXT RNA expression shows 19,112 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where UXT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UXT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UXT survival associations across molecular data types. UXT RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UXT RNA expression–survival associations across cancer types. High UXT expression shows unfavorable associations in KICH, KIRP, LIHC, UCEC and LUAD, but favorable associations in SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for UXT RNA expression.
This table summarizes UXT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UXT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UXT shows higher tumor expression in KIRC, LIHC, COAD, STAD, CHOL and ESCA. The KIRC box plot shows higher UXT RNA expression in tumor versus normal tissue (log2 FC = +0.579, t-test p < 0.001).
This table shows molecular features associated with UXT in patient tissues and cancer cell lines. In patient samples, UXT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UXT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
